Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuicK+fire: AUT00063 in adult unilateral cochlear implant recipients
2015-003929-34Phase 2Completed
- Sponsor
- Autifony Therapeutics
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AUT00063 in Speech perception impairment and Unilateral hearing loss (UHL) (2 arms), sponsored by Autifony Therapeutics. Primary endpoint: Primary: Improvement in speech tests and auditory processing. Started Jan 2016; status: completed.
02
Drugs
AUT00063
03
Conditions
Speech perception impairmentUnilateral hearing loss (UHL)
Beyond the preview
Go deeper on 2015-003929-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003929-34.